Datla said Biological E. would apply for emergency use authorisation (EUA) for the drug based on government advice. The company has assured that even though the price for the vaccine has not been made public yet, it will be one of the more affordable vaccine on offer raising hopes that the company will not be taking advantage of the current crisis. There is speculation that the cost will probably be at around $1.5 per dose which is particularly heartening given that Covaxin, Covishield and Sputnik V are priced at around $10 globally.
India, battling the world's worst jump in coronavirus infections, has partially or fully immunized only about 10% of its 1.35 billion people. It has administered a total of 163 million doses of the AstraZeneca shot and a domestically made one called Covaxin.
The country has also received doses of the Sputnik V vaccine from Russia though it has not been launched yet in the country. India has also urged Pfizer/BioNTech and Moderna to sell their shots to the country.